β胡萝卜素对酒精性肝纤维化的防治效果

Preventive and therapeutic effects of oral β-carotene against alcoholic liver fibrosis

目的:研究β胡萝卜素防治酒精性肝纤维化患者的效果.方法:203例受试者,其中酒精性肝纤维化67例,非酒精性肝纤维化74例,慢性肝炎肝纤维化患者62例.另选60例健康体检者.采用肝纤维化血清透明质酸(HA)、层黏蛋白(LN)、Ⅳ型前胶原(Ⅳ-C)、Ⅲ型前胶原肽(PCⅢ)、血清结缔组织生长因子(CTGF)、血小板衍生生长因子-BB(PDGF-BB)、金属蛋白酶抑制剂-1(TIMP-1)、转化生长因子-β1(TGF-β1)、彩超进行组内组间比较,分析β胡萝卜素防治酒精性肝纤维化患者的效果.结果:HA、LN、Ⅳ-C、PCIII在肝纤维化S0-S1、S2-S4期患者治疗前较健康体检者均有显著性差异(均P<0.01).治疗后,除Ⅳ-C(μg/L)S2-S4期患者较健康体检者有统计学差异外(95.57±15.47,100.16±13.70,96.89±16.41vs84.05±24.16,均P<0.05),其他均无差异.CTGF、PDGF-BB、TIMP-1、TGF-β1在肝纤维化S0-S1、S2-S4期患者治疗较健康体检者均有统计学差异(均P<0.01).治疗后,除CTGF(μg/L)、PDGF-BB(μg/L)S2-S4期患者较健康体检者有统计学差异外(7.74±1.87,7.68±1.72,7.65±1.84vs4.53±1.21;3.51±0.66,3.30±0.65,3.38±0.58vs2.81±0.57,均P<0.01),其他均无差异.彩超显示酒精性肝纤维化患者β胡萝卜素治疗后有所改善.结论:β胡萝卜素对酒精性肝纤维化患者有防治的效果,并与β胡萝卜素防治慢性肝炎肝纤维化患者、非酒精性肝纤维化患者的效果基本一致.

AIM： To observe the preventive and therapeutic effects of oral β-carotene against alcoholic liver fibrosis （ALF）.METHODS： A total of 203 patients,67 patients with alcoholic liver fibrosis,62 patients with chronic hepatitis-associated fibrosis,and 74 patients with non-alcoholic liver fibrosis,were included in this study.One hundred and twenty healthy volunteers were used as controls.Serum hyaluronic acid （HA）,laminin （LN）,type IV procollagen （IV-C）,procollagen peptide III （PCIII）,connective tissue growth factor （CTGF）,platelet derived growth factor-BB （PDGF-BB）,tissue inhibitor of metalloproteinase-1 （TIMP-1）,and transforming growth factor-β1 （TGF-β1） were measured and color Doppler ultrasound were adopted to conduct intra-group and inter-group comparisons to analyze the preventive and therapeutic effects of oral β-carotene against ALF.RESULTS： Before treatment,there were signif icant differences in serum HA,LN,IV-C,and PCIII between patients with liver fibrosis and normal controls （P 〈0.01） as well as between patients with S0-S1 liver fi brosis and those with S2-S4 disease （P〈 0.05）.After treatment,although statistical differences were still noted in serum IV-C between patients with S2-S4 liver fibrosis and normal subjects （95.57 ± 15.47,100.16 ± 13.70,96.89 ± 16.41 vs 84.05 ± 24.16,all P〈 0.05）,there were no signif icant differences in other parameters among different groups.Before treatment,there were signif icant differences in serum CTGF,PDGF-BB,TIMP-1,and TGF-β1 between patients with liver f ibrosis and normal controls （P 〈0.01） as well as between patients with S0-S1 liver fi brosis and those with S2-S4 disease （P 〈0.05）.After treatment,although statistical differences were still noted in serum CTGF and PDGF-BB between patients with S2-S4 liver fibrosis and normal subjects （7.74 ± 1.87,7.68 ± 1.72,7.65 ± 1.84 vs 4.53 ± 1.21;3.51 ± 0.66,3.30 ± 0.65,3.38 ± 0.58 vs 2.81 ± 0.57,all P 〈0.01）,there were no signifi cant differences in other parameters among different groups.Color Doppler ultrasound showed that oral β-carotene could improve ALF.CONCLUSION： Oral β-carotene has preventive and therapeutic effects against ALF.